Yuhua Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuhua Ma has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Shaohua Qu
Department of Breast Surgery, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China
3 shared publications Junhao Zhao
Department of Breast Surgery, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China
2 shared publicationsMei Yang
Department of Breast Surgery, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China
2 shared publicationsYan Zhang
Department of Breast Surgery, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China
2 shared publicationsYiping Wang
Department of Breast Surgery, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China
2 shared publicationsChiseng Lei
Department of Breast Surgery The First Affiliated Hospital of Jinan University Huangpu Road west 510630 Guangzhou China
1 shared publication
Latest Publications
- Open Access
- 4 December 2025
- Published by Elsevier in International Journal of Nursing Studies Advances
- Vol. 10, 100462
Living beyond survival: Experiences of self-management among long-term breast cancer survivors – A qualitative study
- 4 December 2025
- Published by Elsevier in International Journal of Nursing Studies Advances
- Vol. 10, 100462
Open AccessLiving beyond survival: Experiences of self-management among long-term breast cancer survivors – A qualitative study
- Open Access
- 28 December 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-13
Identification and validation of KIF20A for predicting prognosis and treatment outcomes in patients with breast cancer
Breast cancer is a leading cause of cancer-related deaths among women globally. It is imperative to explore novel biomarkers to predict breast cancer treatment response as well as progression. Here, we collected six breast cancer samples and paired normal tissues for high-throughput sequencing. By differential expression analysis, we found 1687 DEGs and identified the top 10 hub genes, including TOP2A, CDK1, BUB1B, KIF11, CCNA2, BUB1, CCNB1, KIF20A, DLGAP5 and CDC20. Univariate and multivariate Cox analyses on the METABRIC database and GSE96058 dataset demonstrated that KIF20A was an independent prognostic predictor for overall survival. KIF20A was positively correlated with cell cycle phases, including the cell cycle process, cycle G2 M phase transition and cell cycle DNA replication initiation. Single-cell analyses revealed that KIF20A was enriched in fibroblasts and endothelial within breast cancer stroma. Meanwhile, multidrug resistance (MDR) genes ABCB1, ABCC1 and ABCG2 were co-expressed with KIF20A in fibroblasts and endothelial cells within the stroma. MTABRIC database confirmed that high expression of KIF20A was positively correlated with treatment efficacy in patients with breast cancer. In conclusion, KIF20A could be served as a predictive biomarker for breast cancer prognosis and treatment outcomes. KIF20A may play a significant role by regulating cell cycle progression and modulating stromal progression in breast cancer. Our findings provided novel molecular insights that can guide personalized treatment strategies in breast cancer.
- 28 December 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-13
Open AccessIdentification and validation of KIF20A for predicting prognosis and treatment outcomes in patients with breast cancer
Breast cancer is a leading cause of cancer-related deaths among women globally. It is imperative to explore novel biomarkers to predict breast cancer treatment response as well as progression. Here, we collected six breast cancer samples and paired normal tissues for high-throughput sequencing. By differential expression analysis, we found 1687 DEGs and identified the top 10 hub genes, including TOP2A, CDK1, BUB1B, KIF11, CCNA2, BUB1, CCNB1, KIF20A, DLGAP5 and CDC20. Univariate and multivariate Cox analyses on the METABRIC database and GSE96058 dataset demonstrated that KIF20A was an independent prognostic predictor for overall survival. KIF20A was positively correlated with cell cycle phases, including the cell cycle process, cycle G2 M phase transition and cell cycle DNA replication initiation. Single-cell analyses revealed that KIF20A was enriched in fibroblasts and endothelial within breast cancer stroma. Meanwhile, multidrug resistance (MDR) genes ABCB1, ABCC1 and ABCG2 were co-expressed with KIF20A in fibroblasts and endothelial cells within the stroma. MTABRIC database confirmed that high expression of KIF20A was positively correlated with treatment efficacy in patients with breast cancer. In conclusion, KIF20A could be served as a predictive biomarker for breast cancer prognosis and treatment outcomes. KIF20A may play a significant role by regulating cell cycle progression and modulating stromal progression in breast cancer. Our findings provided novel molecular insights that can guide personalized treatment strategies in breast cancer.
- Open Access
- 1 November 2024
- Published by Taylor & Francis in Breast Cancer: Targets and Therapy
- Vol. ume 16, 795-810
Identification and Validation of circDOCK1/miR-138-5p/GRB7 Axis for Promoting Breast Cancer Progression
Background: Non-coding RNAs have received increasing attention in human tumors, with RNA interaction networks playing important roles in breast cancer. This study aims to explore novel circular RNAs and their mechanisms of biological function in breast cancer. Methods: Six HER2-positive breast cancer tissues and paired normal tissues were obtained for the whole transcriptome RNA sequencing. Differentially expressed (DE) circRNAs, miRNAs and mRNAs were identified and Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses of DERNAs were performed. DECircRNAs- DEmiRNAs- DEmRNAs networks were constructed and further verified by bioinformatics database analyses, luciferase assays and RIP assays. The expression level of circDOCK1 in breast cancer specimens was measured using qRT-PCR. Functional rescue experiments were conducted to explore the role of circDOCK1/miR-138-5p/GRB7 axis in breast cancer cells. The correlation of circDOCK1 expression and clinicopathologic features of 102 HER2 positive breast cancer patients was analyzed. Results: A total of 6960 DEmRNAs, 133 DE miRNAs and 1691 DE circRNAs were identified from HER2-positive breast cancer tissues and paracancerous tissues. Enrichment Analysis showed that the differential mRNAs were associated with cell division in biological processes and cell cycle and signaling pathways. GO and KEGG analysis demonstrated that DE circRNAs were mainly enriched in double-strand break repair, positive regulation of transcription by RNA polymerase II, nucleoplasma, nucleus, chromatin binding and protein binding. Forty networks of competing endogenous RNAs (ceRNAs) were constructed and circDOCK1/miR-138-5p/GRB7 axis was verified. Functional experiments revealed that the axis promotes migration and invasion of breast cancer cells. CircDOCK1 expression was elevated in breast cancer patients and correlated with adverse clinicopathologic parameters. Patients with high circDOCK1 level had poor outcomes. Conclusion: A novel circDOCK1/miR-138-5p/GRB7 axis promotes HER2 positive breast cancer metastasis and progression, providing a potential therapeutic target in the treatment of breast cancer.
- 1 November 2024
- Published by Taylor & Francis in Breast Cancer: Targets and Therapy
- Vol. ume 16, 795-810
Open AccessIdentification and Validation of circDOCK1/miR-138-5p/GRB7 Axis for Promoting Breast Cancer Progression
Background: Non-coding RNAs have received increasing attention in human tumors, with RNA interaction networks playing important roles in breast cancer. This study aims to explore novel circular RNAs and their mechanisms of biological function in breast cancer. Methods: Six HER2-positive breast cancer tissues and paired normal tissues were obtained for the whole transcriptome RNA sequencing. Differentially expressed (DE) circRNAs, miRNAs and mRNAs were identified and Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses of DERNAs were performed. DECircRNAs- DEmiRNAs- DEmRNAs networks were constructed and further verified by bioinformatics database analyses, luciferase assays and RIP assays. The expression level of circDOCK1 in breast cancer specimens was measured using qRT-PCR. Functional rescue experiments were conducted to explore the role of circDOCK1/miR-138-5p/GRB7 axis in breast cancer cells. The correlation of circDOCK1 expression and clinicopathologic features of 102 HER2 positive breast cancer patients was analyzed. Results: A total of 6960 DEmRNAs, 133 DE miRNAs and 1691 DE circRNAs were identified from HER2-positive breast cancer tissues and paracancerous tissues. Enrichment Analysis showed that the differential mRNAs were associated with cell division in biological processes and cell cycle and signaling pathways. GO and KEGG analysis demonstrated that DE circRNAs were mainly enriched in double-strand break repair, positive regulation of transcription by RNA polymerase II, nucleoplasma, nucleus, chromatin binding and protein binding. Forty networks of competing endogenous RNAs (ceRNAs) were constructed and circDOCK1/miR-138-5p/GRB7 axis was verified. Functional experiments revealed that the axis promotes migration and invasion of breast cancer cells. CircDOCK1 expression was elevated in breast cancer patients and correlated with adverse clinicopathologic parameters. Patients with high circDOCK1 level had poor outcomes. Conclusion: A novel circDOCK1/miR-138-5p/GRB7 axis promotes HER2 positive breast cancer metastasis and progression, providing a potential therapeutic target in the treatment of breast cancer.
- Open Access
- 25 November 2022
- Published by Science Repository OU in Surgical Case Reports
- Vol. 2022 (11) , 1-6
Benign Phyllodes Tumor and Ductal Carcinoma in situ Coexist in the Same Breast Tumor: A Case Report and Review of the Literature
Background: Breast phyllodes tumor (PT), the rare fibroepithelial mammary tumor is composed by mesenchymal and epithelial components, only 1%~2% of which were accompanied by epithelial breast cancer. The incidence of non-invasive ductal carcinoma (DCIS) arising in benign PTs is even rarer. There is no certain treatment for it currently because of the low incidence of PT with DCIS. Case Description: Here, we report a 57-year-old female patient who was diagnosed with ductal carcinoma in situ arising in a benign phyllodes tumor of the breast. Mastectomy and sentinel lymph nodes biopsy were performed, and endocrine therapy was administrated to the patient. No recurrence was noted during follow-up. Conclusion: Since PTs are prone to recurrence, adjuvant therapy should be considered comprehensively by the histopathological results after surgical treatment. In addition, regular follow-up is recommended.
- 25 November 2022
- Published by Science Repository OU in Surgical Case Reports
- Vol. 2022 (11) , 1-6
Open AccessBenign Phyllodes Tumor and Ductal Carcinoma in situ Coexist in the Same Breast Tumor: A Case Report and Review of the Literature
Background: Breast phyllodes tumor (PT), the rare fibroepithelial mammary tumor is composed by mesenchymal and epithelial components, only 1%~2% of which were accompanied by epithelial breast cancer. The incidence of non-invasive ductal carcinoma (DCIS) arising in benign PTs is even rarer. There is no certain treatment for it currently because of the low incidence of PT with DCIS. Case Description: Here, we report a 57-year-old female patient who was diagnosed with ductal carcinoma in situ arising in a benign phyllodes tumor of the breast. Mastectomy and sentinel lymph nodes biopsy were performed, and endocrine therapy was administrated to the patient. No recurrence was noted during follow-up. Conclusion: Since PTs are prone to recurrence, adjuvant therapy should be considered comprehensively by the histopathological results after surgical treatment. In addition, regular follow-up is recommended.